Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Non Operating Income (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Non Operating Income for 12 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 171.43% year-over-year to $5000.0, compared with a TTM value of $14000.0 through Sep 2025, up 227.27%, and an annual FY2024 reading of -$38000.0, down 26.67% over the prior year.
  • Non Operating Income was $5000.0 for Q3 2025 at CytomX Therapeutics, down from $17000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $296000.0 in Q2 2022 and bottomed at -$82000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $11631.6, with a median of $5000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income crashed 1740.0% in 2021, then surged 950.0% in 2025.
  • Year by year, Non Operating Income stood at $7000.0 in 2021, then crashed by 85.71% to $1000.0 in 2022, then skyrocketed by 800.0% to $9000.0 in 2023, then tumbled by 311.11% to -$19000.0 in 2024, then surged by 126.32% to $5000.0 in 2025.
  • Business Quant data shows Non Operating Income for CTMX at $5000.0 in Q3 2025, $17000.0 in Q2 2025, and $11000.0 in Q1 2025.